---
title: "Haemonetics Q1 Profit Declines, But Revenue Rises; Raises FY Revenue Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295093994.md"
description: "Haemonetics reported a decline in Q1 net income to $33.01 million due to higher interest and tax expenses, despite revenue rising 5.6% to $339.38 million. Adjusted EPS increased to $1.14. The company raised its full-year revenue growth outlook to 5%-8% (from 4%-7%) and confirmed adjusted EPS guidance. Shares fell nearly 2% in pre-market trading."
datetime: "2026-08-06T10:55:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295093994.md)
  - [en](https://longbridge.com/en/news/295093994.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295093994.md)
generator: "portal-rs"
---

# Haemonetics Q1 Profit Declines, But Revenue Rises; Raises FY Revenue Outlook

Add  as your preferred news source on Google

 Add Now

Haemonetics Corporation (HAE), a medical technology company, on Thursday reported lower first-quarter profit, as higher interest and other costs and increased tax expenses offset revenue growth. The company also raised its revenue outlook and confirmed djusted EPS guidance.

Net income decreased to $33.01 million from $34.03 million a year earlier. Earnings per share, however, increased to $0.72 from $0.70 on lower shares outstanding.

Income before provision for income taxes increased 5.3% to $47.57 million from $45.17 million. However, income tax expense rose 30.8% to $14.564 million from $11.138 million, weighing on net income.

Net interest and other expense increased to $9.884 million from $8.703 million a year earlier.

Excluding one-time items, earnings were $52.3 million or $1.14 per share, up from last year.

Operating income increased 6.7% to $57.46 million from $53.87 million a year ago.

Revenues increased 5.6% to $339.38 million from $321.39 million.

Looking ahead, Haemonetics now expects revenue growth of 5% - 8%, compared with the previous guidance of 4% - 7%. On an Organic bais, revenue growth is now expected in the range of 4% - 7%, up from the prior forecast of 3% - 6%.

The company maintained its outlook for adjusted earnings per share, expecting growth to be comparable to revenue growth.

Haemonetics shares were down nearly 2% in pre-market trading after closing at $83.60 on Wednesday. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [HAE.US](https://longbridge.com/en/quote/HAE.US.md)

## Related News & Research

- [Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution?](https://longbridge.com/en/news/296298828.md)
- [Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold](https://longbridge.com/en/news/296243457.md)
- [03:46 ETFSLR Deadline: FSLR Investors Have Opportunity to Lead First Solar, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/296319237.md)
- [Haemonetics signs non-exclusive US plasma supply deal with CSL Plasma for NexSys PCS devices, disposables](https://longbridge.com/en/news/296210402.md)
- [HCMC and southern private hospital chapter launched to promote healthcare cooperation](https://longbridge.com/en/news/296428120.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**